Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Shingles: early-phase trial registry

1 of 7 indexed Shingles trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Shingles: 7 US clinical trials tracked, 1 recruiting.

Shingles is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Immorna Biotherapeutics, running 2 of these trials.

Enrollment posture brief

Registry condition shingles

OPEN 1 | RECR 14% | LATE 0 | EARLY 7 | RANK #2497 | SPON 2

Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%Shingles (this)14%
Open-enrollment share among volume-matched conditions near Shingles

Shingles lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Shingles on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Shingles is recruiting below its size-band peers.

    1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Shingles research.

    Immorna Biotherapeutics accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Shingles enrolment sits around 100 participants.

    Median target enrolment is 100 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.

  4. Shingles research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 24

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 4

Named interventions

Most-linked intervention names on Shingles records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

JCXH-105 Biological
2 trials
Shingrix Biological
2 trials
Active Control (Shingrix) Biological
1 trials
Zostavax Biological
1 trials
Shingrix® Biological
1 trials
HZ/su vaccine Biological
1 trials
Amezosvatein Adjuvant Dose Arm F Biological
1 trials
Amezosvatein Adjuvant Dose Arm D Biological
1 trials

US sites by state

Facility locations filed on Shingles trials. A trial with sites in several states counts in each.

Texas 3 trials
Illinois 3 trials
New Jersey 2 trials
Florida 2 trials
Arizona 2 trials
Utah 1 trials
Tennessee 1 trials
South Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Shingles page

7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Shingles condition card totals 7 registered trials; most-linked intervention JCXH-105; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.